English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1).

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice